Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial Open Access
December 1, 2025
Acalabrutinib in patients aged ≥80 years demonstrated 12-month progression-free (PFS) and overall survival (OS) rates of 93.3% and 95.7%, respectively, after a median follow-up of 19 months. Adverse events were severe but rarely included major bleeding or atrial fibrillation. Patient-reported quality of life improved, including amerlioration of frailty.